Search Results for "Neupro"

02:48 EDT 28th April 2015 | BioPortfolio

Matching Channels

None

Matching News

BRIEF-UCB advances Neupro in China

* Announced positive top-line results from two phase 3 studies evaluating Neupro in treatment of patients in China

UCB’s Phase III results for Neupro will back filing in China this year

Belgian drugmaker UCB has announced positive top-line results from two Phase III studies of Neupro (rotigotine transdermal patch) in patients in China with early- and advanced-stage idiopathic Parkins...

UCB to File for China Approval of Parkinson's Disease Patch

UCB of Belgium reported positive results from two China Phase III trials of Neupro, a dopamine agonist patch product, for early and advanced-stage Parkinson's disease. The company said it would comple...

UCB Full Year Report 2014: Core medicines grow by 24% while next wave of new potential solutions for patients advances

"UCB continues its growth path with Cimzia®, Vimpat® and Neupro®, now accounting for 50% of our net sales. We continue to advance and prepare the launches of our next wave of potential new patient ...

Week in Review: WuXi NextCode Leads $15 Million Financing in Claritas Genomics

WuXi PharmaTech, through its WuXi NextCODE Genomics subsidiary, led a $15 million Series B financing in Boston's Claritas Genomics; Armetheon of San Francisco raised $24.3 million from Taiwan/China so...

Important UCB presence at the 2015 American Academy of Neurology Meeting

BRUSSELS, April 20, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on neurology and immunology treatment and research, is sponsoring a total of 24 data presentations at the...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement